LIGAND PHARMACEUTICALS INCORPORATED (LGND) /
The debt of LIGAND PHARMACEUTICALS INCORPORATED over the past 10 years
Chart LIGAND PHARMACEUTICALS INCORPORATED: liquid cash, total debt, net cash, fiscal 2016–2025 Open the chart →At the end of fiscal 2025, the latest fiscal year on file, LIGAND PHARMACEUTICALS INCORPORATED had liquid cash of $733.52M and total debt of $0: net cash of $733.52M. It had more liquid cash than debt at 7 of the 10 year-ends shown. Total debt was highest at the end of fiscal 2019 ($638.96M) and lowest at the end of fiscal 2023 ($0).
Year by year
| Fiscal year | Liquid cash | Total debt* | Net cash* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | $733.52M* | $0 | $733.52M |
| 2024ended Dec 31, 2024 | $256.17M* | $0 | $256.17M |
| 2023ended Dec 31, 2023 | $170.31M* | $0 | $170.31M |
| 2022ended Dec 31, 2022 | $211.87M* | $76.69M | $135.18M |
| 2021ended Dec 31, 2021 | $341.11M* | $320.72M | $20.39M |
| 2020ended Dec 31, 2020 | $411.19M* | $442.29M | -$31.11M |
| 2019ended Dec 31, 2019 | $1.07B* | $638.96M | $430.91M |
| 2018ended Dec 31, 2018 | $773.83M* | $636.3M | $137.53M |
| 2017ended Dec 31, 2017 | $201.66M* | $224.53M | -$22.87M |
| 2016ended Dec 31, 2016 | $141.05M* | $212.91M | -$71.86M |
Fiscal years as LIGAND PHARMACEUTICALS INCORPORATED reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on LIGAND PHARMACEUTICALS INCORPORATED
- The revenue of LIGAND PHARMACEUTICALS INCORPORATED
- The profitability of LIGAND PHARMACEUTICALS INCORPORATED
- The cash flow of LIGAND PHARMACEUTICALS INCORPORATED
- All of LIGAND PHARMACEUTICALS INCORPORATED's financials, charted
Companies of a similar size
- SWXSouthwest Gas Holdings, Inc.
- MACMACERICH CO
- EXLSEXLSERVICE HOLDINGS, INC.
- TXNMTXNM Energy, Inc.
- LADLithia Motors, Inc.
Not investment advice. This page shows what LIGAND PHARMACEUTICALS INCORPORATED filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.